21 July 2022 in Infection & Chemotherapy
Kim Y, et al. Infect Chemother. 2022 Jul;54:e70. https://doi.org/10.3947/ic.2022.0141
1 January 2024 in Infection & Chemotherapy
Seo JW, et al. Infect Chemother. 2024 Mar;56:e11. https://doi.org/10.3947/ic.2024.0024
1 February 2015 in Antimicrobial Agents and Chemotherapy
Vancomycin is frequently inappropriately prescribed, especially as empirical treatment. The aim of this study was to evaluate (i) the amount of inappropriate continued empirical vancomycin use as a proportion of total vancomycin use and (ii) the risk factors associated with inappropriate continued empirical vancomycin use. We reviewed the medical records of adult patients who had been prescribed at least one dose of parenterally administered vancomycin between January and June 2012, in a single tertiary care hospital. When empirically prescribed vancomycin treatment was continued after 96 h without documentation of beta-lactam-resistant Gram-positive microorganisms in clinical specimens with significance, the continuation was considered inappropriate, and the amount used thereafter was considered inappropriately used. We identified risk factors associated with inappropriate continued empirical vancomycin use by multiple logistic regression. During the study period, the amount of parenterally administered vancomycin prescribed was 34.2 defined daily doses (DDDs)/1,000 patient-days (1,084 prescriptions for 971 patients). The amount of inappropriate continued empirical vancomycin use was 8.5 DDDs/1,000 patient-days, which represented 24.9% of the total parenterally administered vancomycin used (8.5/34.2 DDDs/1,000 patient-days). By multivariate analyses, inappropriate continued empirical vancomycin use was independently associated with the absence of any documented etiological organism (adjusted odds ratio [aOR], 1.60 [95% confidence interval {CI}, 1.06 to 2.41]) and suspected central nervous system (CNS) infections (aHR, 2.33 [95% CI, 1.20 to 4.50]). Higher Charlson's comorbidity index scores were inversely associated with inappropriate continued empirical vancomycin use (aHR, 0.90 [95% CI, 0.85 to 0.97]). Inappropriate continued empirical vancomycin use represented 24.9% of the total amount of vancomycin prescribed, which indicates room for improvement.
1 January 2022 in Journal of Korean Medical Science
Jung YH, et al. J Korean Med Sci. 2022 Jun;37(27):e213. https://doi.org/10.3346/jkms.2022.37.e213
1 January 2020 in Dementia and Neurocognitive Disorders
Jung YH, et al. Dement Neurocogn Disord. 2020 Sep;19(3):86-95. https://doi.org/10.12779/dnd.2020.19.3.86